Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition

Hans-Christoph Diener, Cristina Tassorelli, David W Dodick, Stephen D Silberstein, Richard B Lipton, Messoud Ashina, Werner J Becker, Michel D Ferrari, Peter J Goadsby, Patricia Pozo-Rosich, Shuu-Jiun Wang, Jay Mandrekar, International Headache Society Clinical Trials Standing Committee, Hans-Christoph Diener, Cristina Tassorelli, David W Dodick, Stephen D Silberstein, Richard B Lipton, Messoud Ashina, Werner J Becker, Michel D Ferrari, Peter J Goadsby, Patricia Pozo-Rosich, Shuu-Jiun Wang, Jay Mandrekar, International Headache Society Clinical Trials Standing Committee

Abstract

The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. Scientific and clinical developments in headache medicine led to second and third editions in 2000 and 2012, respectively. The current, fourth edition of the Guidelines retains the structure and much content from previous editions. However, it also incorporates evidence from clinical trials published after the third edition as well as feedback from meetings with regulators, pharmaceutical and device manufacturers, and patient associations. Its final form reflects the collective expertise and judgement of the Committee. These updated recommendations and commentary are intended to meet the Society's continuing objective of providing a contemporary, standardized, and evidence-based approach to the conduct and reporting of randomised controlled trials for the acute treatment of migraine attacks.

Keywords: Guidelines; acute treatment of migraine attacks in adults; controlled trials.

References

    1. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991; 11: 1–12.
    1. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia 2000; 20: 765–786.
    1. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia 2012; 32: 6–38.
    1. US Food and Drug Administration, Center for Drug Evaluation and Research. Migraine: Developing drugs for acute treatment guidance for industry, (February 2018).
    1. European Medicines Agency. Concept paper on the need for revision of the guideline on clinical investigation of medicinal product for the treatment of migraine, (13 October 2016).
    1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia 2018; 38: 1–211.
    1. Kallela M, Wessman M, Havanka H, et al. Familial migraine with and without aura: Clinical characteristics and co-occurrence. Eur J Neurol 2001; 8: 441–449.
    1. Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018; 38: 815–832.
    1. Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol 1991; 44: 1147–1157.
    1. Russell MB, Rasmussen BK, Thorvaldsen P, et al. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 1995; 24: 612–618.
    1. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–69.
    1. Lipton RB, Stewart WF. Migraine headaches: Epidemiology and comorbidity. Clin Neurosci 1998; 5: 2–9.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders – DSM 5. Washington: American Psychiatric Association, 2013, pp. 1–947.
    1. Jakovljevic M. The placebo-nocebo response: Controversies and challenges from clinical and research perspective. Eur Neuropsychopharmacol 2014; 24: 333–341.
    1. Jensen K, Tfelt-Hansen P, Hansen EW, et al. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia 1995; 15: 423–429.
    1. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: The scientific and ethical rationale for continued use of placebo controls. Cephalalgia 2005; 25: 124–131.
    1. Autret A, Valade D, Debiais S. Placebo and other psychological interactions in headache treatment. J Headache Pain 2012; 13: 191–198.
    1. Loder E, Freitag FG, Adelman J, et al. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: Results of a large double-blind placebo-controlled trial. Curr Med Res Opin 2005; 21: 381–389.
    1. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 1998; 51: 773–781.
    1. Salonen R, Ashford EA, Gibbs M, et al. Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: A double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. Int J Clin Pract Suppl 1999; 105: 16–24.
    1. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104–1110.
    1. Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia 2010; 30: 1170–1178.
    1. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014; 34: 114–125.
    1. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304–1312.
    1. European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials, (27 March 2015).
    1. Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: Systematic review. BMJ 2010; 340: c2697.
    1. Becker WJ. Acute migraine treatment in adults. Headache 2015; 55: 778–793.
    1. Diener HC, Dodick DW, Goadsby PJ, et al. Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia 2008; 28: 35–40.
    1. ICH Harmonised Tripartite Guideline Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 1999; 18: 1905–1942.
    1. Rolan PE, Martin GR. Zolmitriptan: A new acute treatment for migraine. Expert Opin Investig Drugs 1998; 7: 633–652.
    1. Dahlof C, Lines C. Rizatriptan: A new 5-HT1B/1D receptor agonist for the treatment of migraine. Expert Opin Investig Drugs 1999; 8: 671–685.
    1. Dooley M, Faulds D. Rizatriptan: A review of its efficacy in the management of migraine. Drugs 1999; 58: 699–723.
    1. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: A review of its use in migraine. Drugs 1999; 58: 347–374.
    1. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184–190.
    1. Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 2016; 36: 887–898.
    1. Mitsikostas DD, Belesioti I, Arvaniti C, et al. Patients' preferences for headache acute and preventive treatment. J Headache Pain 2017; 18: 102.
    1. Volans GN. Migraine and drug absorption. Clinical Pharmacokinetics 1978; 3: 313–318.
    1. Volans GN. Absorption of effervescent aspirin during migraine. Br Med J 1974; 4: 265–268.
    1. Tokola RA, Kangasniemi P, Neuvonen PJ, et al. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984; 4: 253–263.
    1. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996; 16: 270–275.
    1. Linde M, Mellberg A, Dahlof C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia 2006; 26: 712–721.
    1. Lanteri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: The TEMPO study. Cephalalgia 2012; 32: 226–235.
    1. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine – ‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28: 383–391.
    1. Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: A placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. J Intern Med 1993; 234: 211–216.
    1. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31: 295–299.
    1. Almas M, Tepper SJ, Landy S, et al. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. Cephalalgia 2014; 34: 126–135.
    1. Lipton RB, Dodick DW, Adelman JU, et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009; 29: 826–836.
    1. Diener HC. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache 2005; 45: 624–631.
    1. Lipton RB, McGinley JS, Shulman KJ, et al. Faster improvement in migraine pain intensity and migraine-related disability at early time points with AVP-825 (sumatriptan nasal powder delivery system) versus oral sumatriptan: A comparative randomized clinical trial across multiple attacks from the COMPASS Study. Headache 2017; 57: 1570–1582.
    1. Cleophas TJ, Zwinderman AH. Random effects models in clinical research. Int J Clin Pharmacol Ther 2008; 46: 421–427.
    1. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985; 5: 5–10.
    1. Larsen BH, Christiansen LV, Andersen B, et al. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand 1990; 81: 464–467.
    1. Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 2005; 65: S50–S58.
    1. National Institute of Neurological Disorders and Stroke Common Data Elements. Headache Version 2.0, (13 December 2018).
    1. Cady RK, Gutterman D, Saiers JA, et al. Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. Cephalalgia 1997; 17: 588–590.
    1. Lipton RB. Methodologic issues in acute migraine clinical trials. Neurology 2000; 55: S3–S7.
    1. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20: 554–560.
    1. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002; 42: S3–S9.
    1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guideline for Good Clinical Practice, (29 May 2017).
    1. Ferrari M. How to assess and compare drugs in the management of migraine: Success rates in terms of response and recurrence. Cephalalgia 1999; 19: S2–S4. discussion, S4–S8.
    1. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259–1287.
    1. MacGregor EA. A review of frovatriptan for the treatment of menstrual migraine. Int J Womens Health 2014; 6: 523–535.
    1. Saxena PR, Tfelt-Hansen P. Triptans, 5-HT1B/1D agonists in the acute treatment of migraines. In: Olesen J, Goadsby PJ, Ramadan NM, et al.(eds). The headaches, Philadelphia: Lippincott Williams & Wilkins, 2006, pp. 469–504. .
    1. Xu H, Han W, Wang J, et al. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain 2016; 17: 113.
    1. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001; 358: 1668–1675.
    1. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633–658.
    1. Goldstein DJ, Offen WW, Moster MB. Efficacy definitions for migraine studies. Cephalalgia 1999; 19: 248–249.
    1. Rodgers AJ, Hustad CM, Cady RK, et al. Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: Comparison to the current FDA requirement using the complete rizatriptan study database. Headache 2011; 51: 356–368.
    1. Lines CR, Vandormael K, Malbecq W. A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain 2001; 93: 185–190.
    1. Ripamonti CI, Brunelli C. Comparison between numerical rating scale and six-level verbal rating scale in cancer patients with pain: A preliminary report. Support Care Cancer 2009; 17: 1433–1434.
    1. European Medicines Agency. Guideline on the clinical development of medicinal products intended for the treatment of pain, (15 December 2016).
    1. Schachtel BP, Thoden WR, Konerman JP, et al. Headache pain model for assessing and comparing the efficacy of over-the-counter analgesic agents. Clin Pharmacol Ther 1991; 50: 322–329.
    1. Cooper SA, Beaver WT. A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther 1976; 20: 241–250.
    1. Tfelt-Hansen P, McCarroll K, Lines C. Sum of Pain Intensity Differences (SPID) in migraine trials. A comment based on four rizatriptan trials. Cephalalgia 2002; 22: 664–666.
    1. Aicher B, Peil H, Peil B, et al. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia 2012; 32: 185–197.
    1. Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: A post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2011; 31: 1466–1476.
    1. Pageler L, Diener HC, Pfaffenrath V, et al. Clinical relevance of efficacy endpoints in OTC trials based on the patients global efficacy assessment. Headache 2009; 49: 646–654.
    1. Lanteri-Minet M, Valade D, Geraud G, et al. Migraine and probable migraine—results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia 2005; 25: 1146–1158.
    1. Schoenen J. Acute migraine therapy: The newer drugs. Curr Opin Neurol 1997; 10: 237–243.
    1. Massiou H, Tzourio C, el Amrani M, et al. Verbal scales in the acute treatment of migraine: Semantic categories and clinical relevance. Cephalalgia 1997; 17: 37–39. discussion 32.
    1. Tfelt-Hansen P. Complete relief (‘IHS’ criterion) or no or mild pain (‘Glaxo’ criterion)? Estimation of relative power in placebo-controlled clinical trials of sumatriptan. In: Olesen J, Tfelt-Hansen P (eds) Headache treatment trial methodology and new drugs Proceedings from the 6th International Headache Research Seminar. New York: Lippincott-Raven, 1997, pp.157–160.
    1. Laska EM, Siegel C, Sunshine A. Onset and duration: Measurement and analysis. Clin Pharmacol Ther 1991; 49: 1–5.
    1. Laska EM, Siegel C. Assessing the onset of relief of a treatment for migraine. Cephalalgia 2000; 20: 724–731.
    1. Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: Comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000; 55: S19–S24.
    1. Tfelt-Hansen P. Early responses in randomized clinical trials of triptans in acute migraine treatment. Are they clinically relevantϿ A comment. Headache 2010; 50: 1198–1200.
    1. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998; 18: 532–538.
    1. Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: A comprehensive review. Headache 2003; 43: 962–974.
    1. Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: A multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003; 43: 202–213.
    1. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998; 38: 737–747.
    1. Goldstein DJ, Roon KI, Offen WW, et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet 2001; 358: 1230–1234.
    1. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000; 20: 455–461.
    1. Cady RK, Dexter J, Sargent JD, et al. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993; 43: 1363–1368.
    1. World Health Organization. The International Classification of Functioning, Disability and Health, (2007).
    1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: Measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6: 429–440.
    1. Schipper H. Why measure quality of life? Can Med Assoc J 1983; 128: 1367–1370.
    1. Ware JE, Jr., Kosinski M, Gandek B, et al. The factor structure of the SF-36 Health Survey in 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1159–1165.
    1. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommitee of the American Academy of Neurology. Neurology 2000; 55: 754–763.
    1. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009; 16: 968–981.
    1. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 1998; 38: 748–755.
    1. Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43: 214–222.
    1. Santanello NC, Hartmaier SL, Epstein RS, et al. Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995; 35: 330–337.
    1. Dahlof C. Minor Symptoms Evaluation (MSE) profile – a questionnaire for assessment of subjective CNS-related symptoms. Scand J Prim Health Care Suppl 1990; 1: 19–25.
    1. Russell MB, Rasmussen BK, Brennum J, et al. Presentation of a new instrument: The diagnostic headache diary. Cephalalgia 1992; 12: 369–374.
    1. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923–926.
    1. Lipton RB, Stewart WF, Ryan RE, Jr., et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55: 210–217.
    1. Dowson A, Bundy M, Salt R, et al. Patient preference for triptan formulations: A prospective study with zolmitriptan. Headache 2007; 47: 1144–1151.
    1. Lainez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006; 26: 246–256.
    1. Christie S, Göbel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2002; 49: 20–29.
    1. Dahlof C. Assessing patient preference in migraine treatment. Cephalalgia 2001; 21: 791–795.
    1. Tullo V, Allais G, Ferrari MD, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: A double-blind, randomized, multicenter, Italian study. Neurol Sci 2010; 31: S51–S54.
    1. Savi L, Omboni S, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011; 12: 219–226.
    1. James KE, Bloch DA, Lee KK, et al. An index for assessing blindness in a multi-centre clinical trial: Disulfiram for alcohol cessation – a VA cooperative study. Stat Med 1996; 15: 1421–1434.
    1. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials 2004; 25: 143–156.
    1. Bang H. Random guess and wishful thinking are the best blinding scenarios. Contemp Clin Trials Commun 2016; 3: 117–121.
    1. Spilker B. Guide to clinical trials, New York: Raven Press, 1991.
    1. EUDRA. EEC note for guidance: Good clinical practice for trials on medicinal products in the European Community. CPMP Working Party on Efficacy of Medicinal Products. Pharmacol Toxicol 1990; 67: 361–372.
    1. Dixon JR., Jr The international conference on harmonization good clinical practice guideline. Qual Assur 1998; 6: 65–74.
    1. Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 2014; 34: 258–267.
    1. Pocock S. Clinical trials. A practical approach, Chichester: John Wiley & Sons, 1984.
    1. Dmitrienko A, Tamhane AC. Gatekeeping procedures with clinical trial applications. Pharm Stat 2007; 6: 171–180.
    1. Dmitrienko A, Wiens BL, Tamhane AC, et al. Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med 2007; 26: 2465–2478.
    1. Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: Extension of the CONSORT 2010 statement. JAMA 2012; 308: 2594–2604.
    1. Gardner MJ, Altman DG. Confidence intervals rather than P values: Estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986; 292: 746–750.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726–732.
    1. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. Int J Surg 2011; 9: 672–677.
    1. Allen C, Jiang K, Malbecq W, et al. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalalgia 1999; 19: 552–556.
    1. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671–677.
    1. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994; 44: 1587–1592.
    1. Russell MB, Rasmussen BK, Fenger K, et al. Migraine without aura and migraine with aura are distinct clinical entities: A study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia 1996; 16: 239–245.
    1. Hauge AW, Hougaard A, Olesen J. On the methodology of drug trials in migraine with aura. Cephalalgia 2010; 30: 1041–1048.
    1. Schankin CJ, Maniyar FH, Digre KB, et al. ‘Visual snow’ – a disorder distinct from persistent migraine aura. Brain 2014; 137: 1419–1428.
    1. Loder E. Design considerations in migraine with aura trials: Learning from experience. Cephalalgia 2010; 30: 1027–1028.
    1. Viana M, Sances G, Linde M, et al. Clinical features of migraine aura: Results from a prospective diary-aided study. Cephalalgia 2017; 37: 979–989.
    1. Hansen JM, Goadsby PJ, Charles AC. Variability of clinical features in attacks of migraine with aura. Cephalalgia 2016; 36: 216–224.
    1. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010; 70: 1505–1518.
    1. Klapper J, Lucas C, Rosjo O, et al. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004; 24: 918–924.
    1. Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia 2005; 25: 735–742.
    1. Winner P, Landy S, Richardson M, et al. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther 2005; 27: 1785–1794.
    1. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012. 15: CD008615.
    1. Cady RK, Martin VT, Geraud G, et al. Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. Headache 2009; 49: 687–696.
    1. Dahlof CG, Rapoport AM, Sheftell FD, et al. Rizatriptan in the treatment of migraine. Clin Ther 1999; 21: 1823–1836. discussion 1821.
    1. D'Amico D, Moschiano F, Usai S, et al. Treatment strategies in the acute therapy of migraine: Stratified care and early intervention. Neurol Sci 2006; 27: S117–S122.
    1. Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000; 55: 1517–1523.
    1. MacGregor EA, Chia H, Vohrah RC, et al. Migraine and menstruation: A pilot study. Cephalalgia 1990; 10: 305–310.
    1. Vetvik KG, Benth JS, MacGregor EA, et al. Menstrual versus non-menstrual attacks of migraine without aura in women with and without menstrual migraine. Cephalalgia 2015; 35: 1261–1268.
    1. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004; 24: 707–716.
    1. Marcus DA, Bernstein CD, Sullivan EA, et al. A prospective comparison between ICHD-II and probability menstrual migraine diagnostic criteria. Headache 2010; 50: 539–550.
    1. International Committee of Medical Journal Editors. Defining the role of authors and contributors, (25 November 2018).

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться